Literature DB >> 18443281

Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance.

Anura P Jayasooriya1, Michael L Mathai, Lesley L Walker, Denovan P Begg, Derek A Denton, David Cameron-Smith, Gary F Egan, Michael J McKinley, Paula D Rodger, Andrew J Sinclair, John D Wark, Harrison S Weisinger, Mark Jois, Richard S Weisinger.   

Abstract

In addition to its role in the storage of fat, adipose tissue acts as an endocrine organ, and it contains a functional renin-angiotensin system (RAS). Angiotensin-converting enzyme (ACE) plays a key role in the RAS by converting angiotensin I to the bioactive peptide angiotensin II (Ang II). In the present study, the effect of targeting the RAS in body energy homeostasis and glucose tolerance was determined in homozygous mice in which the gene for ACE had been deleted (ACE(-/-)) and compared with wild-type littermates. Compared with wild-type littermates, ACE(-/-) mice had lower body weight and a lower proportion of body fat, especially in the abdomen. ACE(-/-) mice had greater fed-state total energy expenditure (TEE) and resting energy expenditure (REE) than wild-type littermates. There were pronounced increases in gene expression of enzymes related to lipolysis and fatty acid oxidation (lipoprotein lipase, carnitine palmitoyl transferase, long-chain acetyl CoA dehydrogenase) in the liver of ACE(-/-) mice and also lower plasma leptin. In contrast, no differences were detected in daily food intake, activity, fed-state plasma lipids, or proportion of fat excreted in fecal matter. In conclusion, the reduction in ACE activity is associated with a decreased accumulation of body fat, especially in abdominal fat depots. The decreased body fat in ACE(-/-) mice is independent of food intake and appears to be due to a high energy expenditure related to increased metabolism of fatty acids in the liver, with the additional effect of increased glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443281      PMCID: PMC2373349          DOI: 10.1073/pnas.0802690105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.

Authors:  E J Henriksen; S Jacob; T R Kinnick; M K Teachey; M Krekler
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

2.  Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity.

Authors:  F Massiera; J Seydoux; A Geloen; A Quignard-Boulange; S Turban; P Saint-Marc; A Fukamizu; R Negrel; G Ailhaud; M Teboul
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

3.  Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice.

Authors:  J Cole; D Ertoy; H Lin; R L Sutliff; E Ezan; T T Guyene; M Capecchi; P Corvol; K E Bernstein
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

4.  Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat.

Authors:  Isabelle Hainault; Guillaume Nebout; Sophie Turban; Bernadette Ardouin; Pascal Ferré; Annie Quignard-Boulangé
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-01       Impact factor: 4.310

5.  Angiotensin II regulates oxygen consumption.

Authors:  Lisa Cassis; Marc Helton; Vicki English; Gerome Burke
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-02       Impact factor: 3.619

6.  Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I.

Authors:  M Brink; S R Price; J Chrast; J L Bailey; A Anwar; W E Mitch; P Delafontaine
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

7.  Metabolic and hemodynamic response of adipose tissue to angiotensin II.

Authors:  M Boschmann; J Ringel; S Klaus; A M Sharma
Journal:  Obes Res       Date:  2001-08

8.  The effects of angiotensin-II on lipolysis in humans.

Authors:  R R Townsend
Journal:  Metabolism       Date:  2001-04       Impact factor: 8.694

9.  Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation.

Authors:  F Massiéra; M Bloch-Faure; D Ceiler; K Murakami; A Fukamizu; J M Gasc; A Quignard-Boulange; R Negrel; G Ailhaud; J Seydoux; P Meneton; M Teboul
Journal:  FASEB J       Date:  2001-10-15       Impact factor: 5.191

10.  Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats.

Authors:  Shea Gilliam-Davis; Valerie S Payne; Sherry O Kasper; Ellen N Tommasi; Michael E Robbins; Debra I Diz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-06       Impact factor: 4.733

View more
  74 in total

1.  Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Authors:  Lawrence Coppey; Eric Davidson; Bao Lu; Craig Gerard; Mark Yorek
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

2.  The renin, angiotensin, aldosterone, and obesity connection.

Authors:  Friedrich Luft
Journal:  J Mol Med (Berl)       Date:  2010-09       Impact factor: 4.599

Review 3.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

4.  Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.

Authors:  Joshua Abd Alla; Andreas Langer; Sherif S Elzahwy; Gökhan Arman-Kalcek; Thomas Streichert; Ursula Quitterer
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

5.  The brain Renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance.

Authors:  Justin L Grobe; Connie L Grobe; Terry G Beltz; Scott G Westphal; Donald A Morgan; Di Xu; Willem J de Lange; Huiping Li; Koji Sakai; Daniel R Thedens; Lisa A Cassis; Kamal Rahmouni; Allyn L Mark; Alan Kim Johnson; Curt D Sigmund
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

6.  Regulated renin release from 3T3-L1 adipocytes.

Authors:  Jason D Fowler; Nathan D Johnson; Thomas A Haroldson; Joy A Brintnall; Julio E Herrera; Stephen A Katz; David A Bernlohr
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-03-17       Impact factor: 4.310

Review 7.  The endocrinology of food intake.

Authors:  Denovan P Begg; Stephen C Woods
Journal:  Nat Rev Endocrinol       Date:  2013-07-23       Impact factor: 43.330

8.  Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome.

Authors:  Undurti N Das
Journal:  J Transl Int Med       Date:  2016-07-07

Review 9.  Adipokines and blood pressure control.

Authors:  Frederique Yiannikouris; Manisha Gupte; Kelly Putnam; Lisa Cassis
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

Review 10.  Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension.

Authors:  Nicole K Littlejohn; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.